The psoriasis genetics/pharmacogenetics group works in collaboration with Professor Jane Worthington and is particularly interested in immunogenetics of early onset psoriasis with key observations around polymorphisms in PTPN22 and IL12/IL23 and collaborative studies with Professors Richard Trembath and Jonathan Barker at King's College London. The group are partners in the:

  • DataPsor UK collaboration with London and Glasgow
  • Wellcome Trust case control consortium on psoriasis

Pharmacogenetic work, funded by Medical Research Council, concentrates on the role of genetics in predicting outcome and side effects of methotrexate therapy. Key observations are based on efflux transporter polymorphisms 'Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis', Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CEM. J Invest Dermatol, February 2008 (Epub ahead of print).